Tested Applications
| Positive WB detected in | A431 cells, mouse skin tissues, rat skin tissues |
| Positive IHC detected in | human tonsillitis tissue, human brown disease, human lung cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF-P detected in | human tonsillitis tissue |
| Positive IF/ICC detected in | A431 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:6000 |
| Immunohistochemistry (IHC) | IHC : 1:1000-1:4000 |
| Immunofluorescence (IF)-P | IF-P : 1:50-1:500 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:400-1:1600 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
28506-1-AP targets Cytokeratin 5 in WB, IHC, IF/ICC, IF-P, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human, mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag25436 Product name: Recombinant human KRT5 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 6-60 aa of BC024292 Sequence: SVSFRSGGSRSFSTASAITPSVSRTSFTSVSRSGGGGGGGFGRVSLAGACGVGGY Predict reactive species |
| Full Name | keratin 5 |
| Calculated Molecular Weight | 590 aa, 62 kDa |
| Observed Molecular Weight | 62 kDa |
| GenBank Accession Number | BC024292 |
| Gene Symbol | Cytokeratin 5 |
| Gene ID (NCBI) | 3852 |
| RRID | AB_2881159 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P13647 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
Cytokeratin 5 (CK5) is a type II intermediate filament protein predominantly expressed in basal epithelial cells of various tissues, including the skin, breast, salivary glands, urinary tract, and upper aerodigestive tract. It is commonly found in specialized cell types such as squamous cells, basal cells, and myoepithelial cells. CK5 forms heterodimers with cytokeratin 14 and plays a crucial role in providing structural support to epithelial cells
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for Cytokeratin 5 antibody 28506-1-AP | Download protocol |
| IHC protocol for Cytokeratin 5 antibody 28506-1-AP | Download protocol |
| WB protocol for Cytokeratin 5 antibody 28506-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The Cytokeratin 5 Polyclonal antibody (Cat# 28506-1-AP) has 17 citations published across 14 journals, including Nature Communications, Bioactive Materials, Cancer Letters, Small, International Journal of Biological Sciences, Stem Cell Research & Therapy, Journal of Investigative Dermatology, Journal of Materials Chemistry B, Human Gene Therapy, FASEB Journal, Journal of Clinical Laboratory Analysis, Journal of Oral Biosciences, Discovery Oncology, and Clinical and Experimental Otorhinolaryngology. Research fields span cancer immunotherapy, organoid biology, stem cell research, wound healing, dermatology, reproductive biology, and epigenetics.
| Species | Application | Title |
|---|---|---|
Bioact Mater Biomimetic hydrogels with mesoscale collagen architecture for patient-derived tumor organoids culture | ||
Bioact Mater Probiotic-inspired hybrid nanovesicles for enhancing immune checkpoint therapy efficiency via tumor immune microenvironment modulation. | ||
Nat Commun An iPSC-based in vitro model recapitulates human thymic epithelial development and multi-lineage specification. | ||
Nat Commun Nanostructured organic sheets sequestering small extracellular vesicles and reactive species to protect against radiation-induced mucositis | ||
Small An Engineered Cytokine-Induced Killer Cell-Derived Nanovesicle Featuring Multiplexed Immune Activation Performances for Enhanced Tumor Therapy. | ||
Cancer Lett The Single Cell Immunogenomic Landscape after Neoadjuvant Immunotherapy combined Chemotherapy in Esophageal Squamous Cell Carcinoma |

























